Harpoon_logo (002).jpg
Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 06, 2020 16:05 ET | Harpoon Therapeutics
Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a $50 million milestone payment from AbbVieAbstract for HPN424 interim Phase 1 data accepted for presentation at...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference
November 26, 2019 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
November 12, 2019 16:05 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 06, 2019 16:05 ET | Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC® product candidates in development for the treatment of prostate and ovarian...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
August 28, 2019 16:05 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 05, 2019 16:05 ET | Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerInitiated Phase 1/2a clinical trial for...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
July 31, 2019 16:05 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 08:30 ET | Harpoon Therapeutics
Continued enrollment of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerNet proceeds of approximately $71 million from completion...
Harpoon_logo (002).jpg
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
April 18, 2019 07:30 ET | Harpoon Therapeutics
HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...